Key facts
- BioInno’s last known valuation is $156.4M (Dec 2021).
- It has raised $48.1M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Tailong VC, Orient Securities Capital Investment Company, Ciit Asset Management, HJ-Investment — 13 tracked in total.
- Status: Privately Held (backing).
Investors
13+- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for BioInno
- ·The full record, as it builds
Funding rounds
No funding rounds for BioInno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioInno
Provider of CDMO process development and GMP production services for cell culture, bioprocessing, and biologics-related technical applications. The company offers outsourcing services, specializing in developing cell therapy and gene therapy drugs for biotechnology and pharmaceutical companies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 4
- Website
- bioinnobio.com/
- Ownership
- Privately Held (backing)
BioInno doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioInno shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioInno in its N-PORT filings yet. We sweep new filings monthly.